Ropes & Gray represented Gilgamesh Pharmaceuticals in a transaction. Gilgamesh Pharmaceuticals announced it has entered into a collaboration and option-to-license agreement with AbbVie (NYSE: ABBV) to...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Novavax Inc. in the transaction. Novavax Inc.(Nasdaq: NVAX) announced it has entered into a co-exclusive licensing agreement with French pharmaceutical company Sanofi...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced it has entered into a research collaboration agreement with Flagship Pioneering and Metaphone Biotechnologies,...
You must be a Standard 1 Year member to access this content.
Ropes & Gray and Wilmer Cutler Pickering Hale and Dorr represented Xilio Therapeutics, Inc. in the deal. Xilio Therapeutics, Inc.(Nasdaq: XLO), announced it has entered into...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised MOMA Therapeutics on the deal. MOMA Therapeutics announced a collaboration and licensing agreement with Swiss pharmaceutical leader Roche (SIX: RO, ROG; OTCQX: RHHBY)....
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Allorion Therapeutics on the transaction. Allorion Therapeutics (Allorion) announced it entered into a global licensing agreement with Avenzo Therapeutics Inc. (Avenzo) to develop and...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Accutar Biotechnology on the transaction. Accutar Biotechnology announced a partnership with Evommune focused on the discovery of novel small molecule drug candidates in...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Acumen Pharmaceuticals on the transaction. Acumen Pharmaceuticals (Nasdaq:ABOS) (“Acumen”) announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics (Nasdaq:HALO) (“Halozyme”). Acumen will...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented LianBio on the deal. LianBio (Nasdaq: LIAN) announced it has entered into an agreement with Bristol Myers Squibb (NYSE:BMY)(BMS), whereby BMS has obtained...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Novo Nordisk on the deal. Novo Nordisk A/S and Valo Health, Inc. announced they have entered into an agreement to discover and...
You must be a Standard 1 Year member to access this content.
Ropes & Gray acted as legal advisor to TransMedics, and Cooley acted as legal advisor to Bridge to Life. TransMedics Group, Inc. (Nasdaq: TMDX) announced that is...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised uniQure N.V. on the deal. uniQure N.V. signed an agreement to sell a portion of the royalty rights due to uniQure from biopharmaceutical...
You must be a Standard 1 Year member to access this content.
